<DOC>
	<DOCNO>NCT00524095</DOCNO>
	<brief_summary>Bronchiectasis chronic pulmonary disease characterize irreversible dilatation bronchus . The current view pathogenesis bronchiectasis considers initial colonization lower respiratory tract different microorganism first step lead inflammatory response characterize neutrophil migration within airway secondary secretion variety tissue-damaging oxidant enzymes neutrophil elastase myeloperoxidase . Persistence microorganisms airways impairment mucus clearance may lead vicious circle event characterize chronic bacterial colonization , persistent inflammatory reaction , progressive tissue damage . The exact prevalence bronchiectasis COPD patient know . It would important ass prevalence , kind bronchiectasis bacterial colonisation . These important feature related natural history COPD therapeutic management patient COPD bronchiectasis . Recent data indicate macrolide long-term treatment inhaled steroid therapy associate reduced rate exacerbation , bronchial colonization inflammation The present study address , relatively large number patient , prevalence bronchiectasis COPD subject use multislice CT scan technique apply unit centrally analyse Unit 2 4 . This analysis determine presence morphology bronchiectasis . Bacterial colonization inflammatory parameter evaluate blood exhalate bronchial condensate . Concerning bacterial colonization molecular biology technique ( Qualitative PCR quantitative real time PCR ) apply . ELISPOT technique evaluation specific immune response used.Electron optical microscopy technique apply bronchial biopsy sample obtain subgroup patient enrol . During second study year , randomize trial patient bronchiectasis perform . Patients randomize receive macrolide inhale steroid standard care 6 month follow-up 6 month . All inflammatory , microbiologic functional parameter describe record . A clinical functional evaluation apply look number exacerbation , quality life , respiratory function parameter .</brief_summary>
	<brief_title>Bronchiectasis Chronic Obstructive Pulmonary Disease ( COPD ) Patients : Role Prophylaxis</brief_title>
	<detailed_description>AIMS OF THE STUDY As previously describe research program aim follow : - definition bronchiectasis prevalence patient affect chronic obstructive pulmonary disease . - After bronchiectasis patient identification , evaluate pathophysiologic implication , microbiologic inflammatory feature subgroup comparison non-bronchiectasis patient . - Finally , research address effect long-term treatment inhaled steroid antibiotic natural history disease pathophysiologic implication . To purpose , study divide two section . In Ist section 400 patient COPD recruit . In patient intend assess prevalence bronchiectasis use CT spiral scanning . We also detect bacterial colonisation real time PCR ELIspot technique , airway inflammation non-invasive method ( exhaled breath condensate ) comparing patient without bronchiectasis . COPD patient bronchiectasis : In population study effect different `` prophylaxis '' i.e. , macrolide inhaled steroid . Details Interventions Proposed STABLE COPD The patient attend clinic morning enrolment , provide write informed consent . During visit medical history record subject undergo physical examination lung function test baseline post salbutamol 200 mcg . CT scan , exhale breath condensate venopuncture also perform . Sputum sample obtain bacterial colonization assessment . Respiratory Assessment : Lung function test perform use Fleish No . 3 heated pneumotachograph ; plethysmographic measurement , thoracic gas volume ( TGV ) , residual volume ( RV ) , total lung capacity ( TLC ) , assess use body plethysmograph ( Werner Gut , Basle , Switzerland ) electronic BTPS compensation constant volume ( 850L ) . DLCO determination perform . CT scan All multislice CT ( MSCT ) scan perform centrally analyse UO 4 . The follow protocol follow 1 . MSCT inspiration TLC slice 1 mm every 10 + 3 expiratory slice RV use three predetermined level ( aortic arch , tracheal carina , right basal common vein ) 2 . Technical parameter : 120 kV , 220 mA , filter bone , FOV include lung , lung parenchyma window ( -600/1600 HU ) 3 . All CT save CD rom Two radiologist analyse CT , every discrepancy solve consensus The diagnosis evaluation bronchiectasis perform accord Webb et al . ( 1 ) : The evaluation perform lobe lobe include lingula ( total lobes= 6 ) 1. bronchiectasis extension lobar base : 0 , 1 ( &lt; 25 % lobe ) , 2 ( 25-50 % ) , 3 ( &gt; 50 % ) - MAX TOT 18 2. severity kind bronchiectasis semi-quantitative , compare diameter adjacent artery : 0 , 1 ( bronchial diameter equal 100-200 % artery diameter ) , 2 ( 200-300 % ) , 3 ( &gt; 300 % ) - MAX TOT 18 3 . Thickness bronchial wall : 0 , 1 ( Thickness &lt; 50 % artery diameter ) , 2 ( 50-100 % ) , 3 ( complete obliteration lumen Hydro-air level ) - MAX TOT 18 4 . Evaluation emphysema ( visual score three level ( inspiration ) ( aortic arch , carina , vein ) 5 . Evaluation air trap expiration ( idem ) 6 . Bullae 7 . Ground glass area ( extension visual score ) 8. bronchiolitis : prevalent site , lobar involvement , severity ( 0,1,2,3 ) 9 . Pulmonary artery diameter ( pathological &gt; 2,9 cm ) 10 . Other feature Exhaled breath condensate : Exhaled breath condensate collect use condenser , allow non-invasive collection nongaseous component expiratory air ( EcoScreen , Jaeger , Germany ) . Subjects breathe tidally mouthpiece connect inlet 8 min wear nose-clip . The mouthpiece also use saliva trap . Approximately 1 ml breath condensate collect store -70° C. IL-6 , IL-8 , TNF-a cysteinyl-leukotrienes ( cys-LTs ) measure specific enzyme immunoassay ( EIA ) ( Cayman Chemical , Ann Arbor , MI ) . Moreover proteomic analysis perform subset patient enrol UO1 previously report ( 2 ) ; briefly , one-dimensional two-dimensional electrophoresis perform qualitative evaluation mass spectrometry analysis , gel stain silver nitrate , without glutaraldehyde sensitization step formaldehyde impregnation solution . Spot volumes calculate use Image J 1.29x ( W. Rasband , National Institutes Health , Bethesda , Maryland ) one-dimensional gel , PDQUEST ( Biorad , Hercules , California ) two-dimensional gel . Serum Samples : Serum aliquot arrange duplicate store - 20°C time analysis . IL-6 , IL-8 , TNF-a cysteinyl-leukotrienes ( cys-LTs ) measure specific enzyme immunoassay ( EIA ) ( Cayman Chemical , Ann Arbor , MI ) . C-reactive protein procalcitonin also measure . ( 3 ) UO 1 The ex-vivo Enzyme-Linked ImmunoSPOT ( ELISPOT ) assay sensitive tool detect quantify antigen-specific T-cell response , detect enumerate T-cells produce one cytokine response specific antigens . This technique already use detect low number antigen-specific T-cells infectious disorder , particular emphasis intracellular pathogen Mycobacterium tuberculosis . The ELISPOT technique become standard reference monitoring many infectious disease , include HIV infection , become use advanced clinical immunological application , detection antigen-specific T cell immune response oncogene peptide . In context propose project , ELISPOT technology use detect presence systemic ( blood ) local ( bronchoalveolar lavage ) antigen-specific response use peptide pool non tuberculous mycobacteria intracellular bacteria ( Mycoplasma pneumoniae ) , bacteria ( Pseudomonas spp ) fungi ( Aspergillus specie ) . The ELISPOT test perform sample whole blood ( Ficoll separation peripheral mononuclear cell ) bronchoalveolar cell measure number T cell produce interferon-gamma overnight incubation specific antigenic peptide pool . ( 4-8 ) Sputum collection : A sample spontaneous sputum obtain patient . Alternatively induced sputum accord Pizzichini , et al ( 9 ) collect . In summary , induced sputum obtain inhalation hypertonic saline water 3 % 20 minute use ultrasonic nebulizer ( Ultraneb 2000 ; DeVilbiss Healthcare Inc , Somerset , PS , USA ) .Only sample sputum degree IV V Murray-Washington classification ( 10 ) process . A sputum sample frozen -70°C bacterial DNA detection use PCR ( qualitative analysis ) real time PCR ( quantitative analysis ) technique . The following Bacteria wil detect use standard protocol use UO1 : H. influenzae , M. catarrhalis , S. pneumoniae , P. aeruginosa , Mycoplasma pneumoniae , Chlamydia pneumoniae . An aliquot cultivate use standard microbiologic technique Patients 400 patient recruit UO 1,2,3 e 5 . All CT scan collect examined UO 4 . UO2 serve second observer double-blind fashion ; discrepancy solve consensus . One subgroup patient stable COPD ( n=15 ) subgroup patient COPD bronchiectasis ( n=15 ) undergo bronchoscopy biopsy collection . Subjects premedicated atropine anesthetize topically lidocaine . Bronchoscopy perform flexible fiberoptic bronchoscope . Bronchial biopsy take bronchoscope standard forceps carina basal segment bronchus right low lobe . From area two specimen obtain patient . Bronchial biopsy obtain prepared electronic light microscopy analysis ( UO3 UO 1 ) . Sample size : expect least 30 % prevalence bronchiectasis mean 120 patient include second step study ( 11 ) COPD PATIENTS WITH BRONCHIECTASIS : In population study effect different `` prophylaxis '' i.e . macrolide inhale steroid . The population follow 12 month . The following procedure perform every 3 month exacerbation : Clinical assessment , Exhaled breath condensate , Serum Sampling , Sputum collection . On biological sample previously describe technique plus renal hepatic function test ( safety ) perform . Sputum culture perform assess bacterial flora resistance pattern . Design study : 120 patient randomize 3 group ( 40 pt ) receive : 1 . Standard care 2. azithromycin 500 mg OD 3 day week ( Monday , Wednesday , Friday ) 6 month inhale steroid ( fluticasone 500 ug bid ) 6 month 3. inhaled steroid ( fluticasone 500 ug bid ) 6 month azithromycin 500 mg OD 3 day week ( Monday , Wednesday , Friday ) 6 month End-points : PRIMARY - effect treatment bronchial inflammation parameter SECONDARY - effect treatment exacerbation frequency - effect treatment pulmonary function Sample size : We expect 40 % difference treat non-treated patient least one among TNFa , IL6 , IL8 , cysteinyl-leukotrienes . In case need 35 treated patient ( arm ) 35 non-treated patient alpha error 0.05 beta 0.1 .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Azithromycin</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Smokers former smoker least 10 packyears COPD demonstrate forced spirometry FEV1 &gt; 0,7 L , FEV1 postBD &lt; 60 % FEV1/FVC &lt; 70 % Bronchodilator test perform inclusion 6 month inclusion negative ( increase FEV1 &lt; 200 ml 12 % , 10 minute administration 2 puff salbutamol Stable phase define clinical criterion attend investigator , least 6 week last exacerbation Informed consent Patients receive oral corticosteroid dose another immunosuppressor Formal contraindication sputum collection impossibility obtain sample sputum valid analysis . Allergy steroid macrolides</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>prophylaxis</keyword>
	<keyword>Antibiotic</keyword>
	<keyword>inhaled steroid</keyword>
	<keyword>bronchiectasis</keyword>
	<keyword>prevalence</keyword>
	<keyword>chronic bronchitis</keyword>
</DOC>